KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Depreciation: 2017-2021

Historic Accumulated Depreciation for Aquestive Therapeutics (AQST) over the last 3 years, with Mar 2021 value amounting to $37.8 million.

  • Aquestive Therapeutics' Accumulated Depreciation fell 2.39% to $37.8 million in Q1 2021 from the same period last year, while for Mar 2021 it was $37.8 million, marking a year-over-year decrease of 2.39%. This contributed to the annual value of $40.9 million for FY2020, which is 7.45% up from last year.
  • As of Q1 2021, Aquestive Therapeutics' Accumulated Depreciation stood at $37.8 million, which was down 7.45% from $40.9 million recorded in Q4 2020.
  • In the past 5 years, Aquestive Therapeutics' Accumulated Depreciation ranged from a high of $40.9 million in Q4 2020 and a low of $32.0 million during Q4 2017.
  • Its 3-year average for Accumulated Depreciation is $38.3 million, with a median of $38.0 million in 2019.
  • Per our database at Business Quant, Aquestive Therapeutics' Accumulated Depreciation increased by 9.95% in 2018 and then declined by 2.39% in 2021.
  • Aquestive Therapeutics' Accumulated Depreciation (Quarterly) stood at $32.0 million in 2017, then rose by 9.95% to $35.2 million in 2018, then climbed by 8.11% to $38.0 million in 2019, then grew by 7.45% to $40.9 million in 2020, then declined by 2.39% to $37.8 million in 2021.
  • Its Accumulated Depreciation was $37.8 million in Q1 2021, compared to $40.9 million in Q4 2020 and $40.2 million in Q3 2020.